Actionable news
0
All posts from Actionable news
Actionable news in GWPH: GW Pharmaceuticals Plc,

Gw Pharmaceuticals And The Government Of New South Wales Announce

The following excerpt is from the company's SEC filing.

a Strategic Agreement to Study Epidiolex® and CBDV

in a Clinical Trial and Research Program for Children with Epilepsy

: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that a Memorandum of Understanding (MOU) has been signed with the Government of New South Wales (NSW) in Australia to progress a research program for Epidiolex® (cannabidiol or CBD) and cannabidivarin (CBDV) in children with severe, drug resistant childhood epilepsy.

“GW is pleased to have been able to respond to the needs of the New South Wales government and its citizens by establishing this research program for cannabinoid-based medicines in children with treatment resistant epilepsy,” stated Justin Gover, GW’s Chief Executive Officer. “As part of this research partnership, GW expects to advance clinical trials in Australia for both Epidiolex and our earlier stage pipeline product CBDV.”

“This confirms NSW’s position as a world leader in cannabinoid research and demonstrates the determination of our Government to ensure we secure these groundbreaking trials,” stated NSW Premier Mike Baird. “Our research and development is driven by compassion for those suffering so we hope that these initiatives will bring relief to many children and their loved ones.”

The MOU will facilitate:

A world first, Phase 2 clinical trial in children for GW’s novel product containing the cannabinoid cannabidivarin (CBDV)

A compassionate access program for Epidiolex which is currently in Phase 3 clinical trials with the U.S. Food and Drug Administration for Dravet syndrome and Lennox-Gastaut syndrome, two rare, extremely debilitating epilepsy syndromes that begin in infancy or early childhood.

Provision for NSW to host additional Phase 3 clinical trials of Epidiolex in children with treatment-resistant epilepsy

A Phase 4 clinical trial of Epidiolex based on Phase 3 studies

As part of this...


More